Intuitive Surgical, Inc.
$399.05-$8.19 (-2.0%)
Last close · Data as of Nov 20, 2026
- Market cap
- $148.3B
- P/E
- 51.9x
- EV / EBITDA
- 39.3x
- Revenue
- $10.1B
- Net margin
- 28.4%
- ROCE
- 16.5%
Price chart
Technical chartScreen technicals →-27.7% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -8.9%
- 3M
- +6.6%
- 6M
- -11.1%
- 1Y
- -27.7%
- 5Y
- +14.5%
52-week range
Day change -$8.19 (-2.0%) from $407 to $399 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in ISRG, bought on each weekday since 2021.
News & filings
What Intuitive Surgical filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockStrengthOperating margin of 29.3% against a peer median of 19.6%.
Concerns (1)
- The P/E of 51.9 is 104% above the peer median of 25.5.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally.
Read moreShow less
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
- Sector
- Healthcare
- Shares outstanding
- 355.1M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $148.3B
- P/E
- 51.9x
- P/B
- 8.3x
- EV / EBITDA
- 39.3x
- EV / Sales
- 14.2x
- P/S
- 14.7x
- 52-week high
- $592.85
- 52-week low
- $332.02
Profitability
- Operating margin
- 29.3%
- Net margin
- 28.4%
- EBITDA margin
- 36.0%
- ROE
- 16.0%
- ROCE
- 16.5%
- ROA
- 14.0%
- Asset turnover
- 0.49
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $10.1B
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 20.5%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- 17.4%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- $2.5B
Solvency
- Current ratio
- 4.87
- Debt / Equity
- 0.00
- Debt / Assets
- 0.00
- CFO / Net profit
- 1.06
- Cash / Market cap
- 4.0%
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Revenue | $10.1B |
| Cost of revenue | $3.4B |
| Gross profit | $6.6B |
| Operating expenses | $3.7B |
| Research and development | $1.3B |
| Selling, general and administrative | $2.4B |
| Operating income | $2.9B |
| Interest and other | $365.9M |
| Pretax income | $3.3B |
| Tax and other | $434.8M |
Revenue and net profit
Revenue grew 20.5% in FY2025; net profit is the dashed line.
| Date | Revenue |
|---|---|
| FY2022 | $6.2B |
| FY2023 | $7.1B |
| FY2024 | $8.4B |
| FY2025 | $10.1B |
Cash flows
FY2025: $3.0B from operations, $2.5B free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | $1.5B | $958.4M |
| FY2023 | $1.8B | $749.6M |
| FY2024 | $2.4B | $1.3B |
| FY2025 | $3.0B | $2.5B |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $10.1B+20.5%1Y
- EBITDA
- $3.6B+27.2%1Y
- Cash from operations
- $3.0B+25.5%1Y
- Free cash flow
- $2.5B+91.0%1Y
- Revenue CAGR, 3Y
- 17.4%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $10.1B | $3.6B | — | $2.5B | — | +20.5% | — |
Monthly returns
Month-by-month returns of ISRG across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $20.5B |
| Current assets | $9.8B |
| Non-current assets | $10.7B |
| Liabilities | $2.5B |
| Current liabilities | $2.0B |
| Non-current liabilities | $510.8M |
| Equity | $17.9B |
| Paid-in capital | $10.8B |
| Retained earnings | $7.0B |
| Minority interest | $117.7M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; ISRG highlighted.
P/E against peers
ISRG trades at 51.9x earnings against a peer median of 25.5x (a 104% premium).
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Intuitive Surgical, Inc.ISRGthis companyP/E ↑ premium | $148.3B | 51.9x | 8.3x | 16.0% | 39.3x |
| Thermo Fisher Scientific Inc.TMO | $179.1B | 26.7x | 3.4x | 12.6% | 18.1x |
| Gilead Sciences, Inc.GILD | $160.4B | 18.8x | 7.1x | 37.5% | 12.9x |
| Abbott LaboratoriesABT | $158.1B | 24.2x | 3.0x | 12.5% | 13.5x |
| Pfizer Inc.PFE | $146.4B | 18.8x | 1.7x | 9.0% | 12.5x |
| Danaher CorporationDHR | $132.1B | 36.6x | 2.5x | 6.9% | 21.2x |
| CVS Health CorporationCVS | $121.0B | 68.4x | 1.6x | 2.4% | 19.5x |
| Bristol-Myers Squibb CompanyBMY | $115.6B | 16.4x | 6.3x | 38.2% | 10.0x |
| Stryker CorporationSYK | $115.5B | 35.6x | 5.2x | 14.5% | 20.2x |
| Peer median | — | 25.5x | 3.2x | 12.5% | 15.8x |
Year-to-date ROI
ISRG since 1 January, against earlier years.
Historical volatility
ISRG's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | 25.3% |
| FY2023 | 24.8% |
| FY2024 | 28.1% |
| FY2025 | 29.3% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $10.1B |
| Cost of revenueCost Of Revenue | $3.4B |
| Gross profitGross Profit | $6.6B |
| Operating expensesOperating Expense | $3.7B |
| Research and developmentResearch And Development | $1.3B |
| Selling, general and administrativeSelling General And Administration | $2.4B |
| Total expensesTotal Expenses | $7.1B |
| Operating incomeOperating Income | $2.9B |
| Interest and other | |
| Pretax incomePretax Income | $3.3B |
| TaxTax Provision | $434.8M |
| Net income | |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $20.5B |
| Current assetsCurrent Assets | $9.8B |
| Non-current assetsTotal Non Current Assets | $10.7B |
| LiabilitiesTotal Liabilities Net Minority Interest | $2.5B |
| Current liabilitiesCurrent Liabilities | $2.0B |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $510.8M |
| EquityTotal Equity Gross Minority Interest | $17.9B |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | $3.0B |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | $3.0B |
| Net income, continuing operationsNet Income From Continuing Operations | $2.9B |
| Depreciation and amortisationDepreciation And Amortization | $677.1M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $677.1M |
| Depreciation | $614.7M |
| Amortization cash flowAmortization Cash Flow | $62.4M |
| Amortization of intangiblesAmortization Of Intangibles | $62.4M |
| Stock-based compensationStock Based Compensation | $788.2M |
| Deferred taxDeferred Tax | $19.1M |
| Deferred income taxDeferred Income Tax | $19.1M |
| Operating gains and lossesOperating Gains Losses | -$58.2M |
| Gain loss on investment securitiesGain Loss On Investment Securities | -$57.2M |
| Gain loss on sale of businessGain Loss On Sale Of Business | -$1.0M |
| Change in working capitalChange In Working Capital | -$1.3B |
| Other non-cash itemsOther Non Cash Items | — |
| Investing cash flowInvesting Cash Flow | $665.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | $665.8M |
| Capital expenditureCapital Expenditure | -$539.8M |
| Purchase of PP&EPurchase Of PPE | — |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$539.8M |
| AcquisitionsPurchase Of Business | -$13.9M |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$13.9M |
| Purchase of investmentsPurchase Of Investment | -$1.2B |
| Sale of investmentsSale Of Investment | $2.4B |
| Net investment purchases and salesNet Investment Purchase And Sale | $1.2B |
| Financing cash flowFinancing Cash Flow | -$2.4B |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$2.4B |
| Net common stock issuedNet Common Stock Issuance | -$2.3B |
| Common stock repurchasedCommon Stock Payments | -$2.3B |
| Share buybacksRepurchase Of Capital Stock | -$2.3B |
| Stock options exercisedProceeds From Stock Option Exercised | $350.3M |
| Other financing chargesNet Other Financing Charges | -$419.1M |
| Change in cashChanges In Cash | $1.3B |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 1,280.0% |
| Cash at the start of the yearBeginning Cash Position | $2.1B |
| Cash at the end of the yearEnd Cash Position | $3.4B |
| Free cash flowFree Cash Flow | $2.5B |
| Supplemental |
Learn while you research
Academy chapters picked for Intuitive Surgical, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Valuation Multiples ExplainedThis stock trades at a P/E of 51.9, learn when high multiples are justified.6 min read
- 03 Growth Investing21% revenue growth is in the top tier, learn how to value growth.7 min read
- 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read